Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot Study
BackgroundGlycemic variability is associated with the development of diabetic complications through the activation of oxidative stress. This study aimed to evaluate the effects of a dipeptidyl peptidase 4 inhibitor, vildagliptin, or a thiazolidinedione, pioglitazone, on glycemic variability and oxid...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Academya Publishing Co.
2017-06-01
|
Series: | Endocrinology and Metabolism |
Subjects: | |
Online Access: | https://e-enm.org/Synapse/Data/PDFData/2008ENM/enm-32-241.pdf |
id |
doaj-783f544163fa4453b788fe4e2f9b68b6 |
---|---|
record_format |
Article |
spelling |
doaj-783f544163fa4453b788fe4e2f9b68b62020-11-25T00:47:11ZengAcademya Publishing Co.Endocrinology and Metabolism2093-596X2093-59782017-06-0132224124710.3803/EnM.2017.32.2.241Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot StudyNam Hoon Kim0Dong-Lim Kim1Kyeong Jin Kim2Nan Hee Kim3Kyung Mook Choi4Sei Hyun Baik5Sin Gon Kim6Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.Division of Endocrinology and Metabolism, Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea.Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.BackgroundGlycemic variability is associated with the development of diabetic complications through the activation of oxidative stress. This study aimed to evaluate the effects of a dipeptidyl peptidase 4 inhibitor, vildagliptin, or a thiazolidinedione, pioglitazone, on glycemic variability and oxidative stress in patients with type 2 diabetes.MethodsIn this open label, randomised, active-controlled, pilot trial, individuals who were inadequately controlled with metformin monotherapy were assigned to either vildagliptin (50 mg twice daily, n=17) or pioglitazone (15 mg once daily, n=14) treatment groups for 16 weeks. Glycemic variability was assessed by calculating the mean amplitude of glycemic excursions (MAGE), which was obtained from continuous glucose monitoring. Urinary 8-iso prostaglandin F2α, serum oxidised low density lipoprotein, and high-sensitivity C-reactive protein were used as markers of oxidative stress or inflammation.ResultsBoth vildagliptin and pioglitazone significantly reduced glycated hemoglobin and mean plasma glucose levels during the 16-week treatment. Vildagliptin also significantly reduced the MAGE (from 93.8±38.0 to 70.8±19.2 mg/dL, P=0.046), and mean standard deviation of 24 hours glucose (from 38±17.3 to 27.7±6.9, P=0.026); however, pioglitazone did not, although the magnitude of decline was similar in both groups. Markers of oxidative stress or inflammation including urinary 8-iso prostaglandin F2α did not change after treatment in both groups.ConclusionIn this 16-week treatment trial, vildagliptin, but not pioglitazone, reduced glycemic variability in individuals with type 2 diabetes who was inadequately controlled with metformin monotherapy, although a reduction of oxidative stress markers was not observed.https://e-enm.org/Synapse/Data/PDFData/2008ENM/enm-32-241.pdfGlycemic variabilityDipeptidyl-peptidase IV inhibitorsThiazolidinedionesDiabetes mellitus, type 2 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Nam Hoon Kim Dong-Lim Kim Kyeong Jin Kim Nan Hee Kim Kyung Mook Choi Sei Hyun Baik Sin Gon Kim |
spellingShingle |
Nam Hoon Kim Dong-Lim Kim Kyeong Jin Kim Nan Hee Kim Kyung Mook Choi Sei Hyun Baik Sin Gon Kim Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot Study Endocrinology and Metabolism Glycemic variability Dipeptidyl-peptidase IV inhibitors Thiazolidinediones Diabetes mellitus, type 2 |
author_facet |
Nam Hoon Kim Dong-Lim Kim Kyeong Jin Kim Nan Hee Kim Kyung Mook Choi Sei Hyun Baik Sin Gon Kim |
author_sort |
Nam Hoon Kim |
title |
Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot Study |
title_short |
Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot Study |
title_full |
Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot Study |
title_fullStr |
Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot Study |
title_full_unstemmed |
Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot Study |
title_sort |
effects of vildagliptin or pioglitazone on glycemic variability and oxidative stress in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a 16-week, randomised, open label, pilot study |
publisher |
Academya Publishing Co. |
series |
Endocrinology and Metabolism |
issn |
2093-596X 2093-5978 |
publishDate |
2017-06-01 |
description |
BackgroundGlycemic variability is associated with the development of diabetic complications through the activation of oxidative stress. This study aimed to evaluate the effects of a dipeptidyl peptidase 4 inhibitor, vildagliptin, or a thiazolidinedione, pioglitazone, on glycemic variability and oxidative stress in patients with type 2 diabetes.MethodsIn this open label, randomised, active-controlled, pilot trial, individuals who were inadequately controlled with metformin monotherapy were assigned to either vildagliptin (50 mg twice daily, n=17) or pioglitazone (15 mg once daily, n=14) treatment groups for 16 weeks. Glycemic variability was assessed by calculating the mean amplitude of glycemic excursions (MAGE), which was obtained from continuous glucose monitoring. Urinary 8-iso prostaglandin F2α, serum oxidised low density lipoprotein, and high-sensitivity C-reactive protein were used as markers of oxidative stress or inflammation.ResultsBoth vildagliptin and pioglitazone significantly reduced glycated hemoglobin and mean plasma glucose levels during the 16-week treatment. Vildagliptin also significantly reduced the MAGE (from 93.8±38.0 to 70.8±19.2 mg/dL, P=0.046), and mean standard deviation of 24 hours glucose (from 38±17.3 to 27.7±6.9, P=0.026); however, pioglitazone did not, although the magnitude of decline was similar in both groups. Markers of oxidative stress or inflammation including urinary 8-iso prostaglandin F2α did not change after treatment in both groups.ConclusionIn this 16-week treatment trial, vildagliptin, but not pioglitazone, reduced glycemic variability in individuals with type 2 diabetes who was inadequately controlled with metformin monotherapy, although a reduction of oxidative stress markers was not observed. |
topic |
Glycemic variability Dipeptidyl-peptidase IV inhibitors Thiazolidinediones Diabetes mellitus, type 2 |
url |
https://e-enm.org/Synapse/Data/PDFData/2008ENM/enm-32-241.pdf |
work_keys_str_mv |
AT namhoonkim effectsofvildagliptinorpioglitazoneonglycemicvariabilityandoxidativestressinpatientswithtype2diabetesinadequatelycontrolledwithmetforminmonotherapya16weekrandomisedopenlabelpilotstudy AT donglimkim effectsofvildagliptinorpioglitazoneonglycemicvariabilityandoxidativestressinpatientswithtype2diabetesinadequatelycontrolledwithmetforminmonotherapya16weekrandomisedopenlabelpilotstudy AT kyeongjinkim effectsofvildagliptinorpioglitazoneonglycemicvariabilityandoxidativestressinpatientswithtype2diabetesinadequatelycontrolledwithmetforminmonotherapya16weekrandomisedopenlabelpilotstudy AT nanheekim effectsofvildagliptinorpioglitazoneonglycemicvariabilityandoxidativestressinpatientswithtype2diabetesinadequatelycontrolledwithmetforminmonotherapya16weekrandomisedopenlabelpilotstudy AT kyungmookchoi effectsofvildagliptinorpioglitazoneonglycemicvariabilityandoxidativestressinpatientswithtype2diabetesinadequatelycontrolledwithmetforminmonotherapya16weekrandomisedopenlabelpilotstudy AT seihyunbaik effectsofvildagliptinorpioglitazoneonglycemicvariabilityandoxidativestressinpatientswithtype2diabetesinadequatelycontrolledwithmetforminmonotherapya16weekrandomisedopenlabelpilotstudy AT singonkim effectsofvildagliptinorpioglitazoneonglycemicvariabilityandoxidativestressinpatientswithtype2diabetesinadequatelycontrolledwithmetforminmonotherapya16weekrandomisedopenlabelpilotstudy |
_version_ |
1725261299132137472 |